GD2-directed NAMPT inhibition using antibody-drug conjugates in neuroblastoma

Key Points

• NAMPT inhibition via GD2-directed antibody-drug conjugates shows promise against neuroblastoma tumors.
• This approach could significantly improve treatment outcomes in neuroblastoma, with preliminary efficacy observed.
• In vitro experiments validate the effectiveness of antibody-drug conjugates in reducing cancer cell viability.
• These findings highlight a potential new avenue for targeted cancer therapies, though further clinical validation is required.